ReviewTherapeutics and clinical risk management2015
Novel targeted therapies in chordoma: an update.
Review in Therapeutics and clinical risk management, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 60 citations in OpenAlex.
- Apparent diffusion coefficient as a prognostic factor in clival chordoma.Scientific reports · 2021Trial
- Gas Plasma Technology and Immunogenic Cell Death: Implications for Chordoma Treatment.Cancers · 2025Review
- Chordoma Genetic Aberrations and Targeted Therapies Panorama: A Systematic Literature Review.Journal of clinical medicine · 2024Review
- Integrated Molecular and Histological Insights for Targeted Therapies in Mesenchymal Sinonasal Tract Tumors.Current oncology reports · 2024Review
- Cardiac self-limiting rhabdomyomas in a neonatal patient with tuberous sclerosis complex: a case report with negative genetic testing.Frontiers in pediatrics · 2023Article
- Chordoma:Skeletal radiology · 2021Article
- Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy.Journal of neuro-oncology · 2020Article
- Deficiency ofOncoTargets and therapy · 2020Article
- Long and Very-Long-Chain Ceramides Correlate with A More Aggressive Behavior in Skull Base Chordoma Patients.International journal of molecular sciences · 2019Article
- Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma.Journal of neuro-oncology · 2019Article
- Skull base chordoma treated with proton therapy: A systematic review.Surgical neurology international · 2019Article
- Article
- Clinical outcome of proton therapy for patients with chordomas.Radiation oncology journal · 2018Article
- Humeral metastasis of sacrococcygeal chordoma detected by fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography: A case report.Radiology case reports · 2018Article
- Tumor Reduction with Pazopanib in a Patient with Recurrent Lumbar Chordoma.Case reports in oncological medicine · 2018Article
- Review
- Establishment and genomic characterization of the new chordoma cell line Chor-IN-1.Scientific reports · 2017Article
- Chordoma Occurs in Young Children With Tuberous Sclerosis.Journal of neuropathology and experimental neurology · 2017Article
- Immunophenotypic features of dedifferentiated skull base chordoma: An insight into the intratumoural heterogeneity.Contemporary oncology (Poznan, Poland) · 2017Review
- Spinal stereotactic body radiotherapy following intralesional curettage with separation surgery for initial or salvage chordoma treatment.Neurosurgical focus · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chordomas are rare, locally aggressive skull base neoplasms known for local recurrence and not-infrequent treatment failure. Current evidence supports the role of maximal safe surgical resection. In addition to open skull-base approaches, the endoscopic endonasal approach to clival chordomas has been reported with favorable albeit early results. Adjuvant radiation is prescribed following complete resection, alternatively for gross residual disease or at the time of recurrence. The modalities of adjuvant radiation therapy reported vary widely and include proton-beam, carbon-ion, fractionated photon radiotherapy, and photon and gamma-knife radiosurgery. As of now, no direct comparison is available, and high-level evidence demonstrating superiority of one modality over another is lacking. While systemic therapies have yet to form part of any first-line therapy for chordomas, a number of targeted agents have been evaluated to date that inhibit specific molecules and their respective pathways known to be implicated in chordomas. These include EGFR (erlotinib, gefitinib, lapatinib), PDGFR (imatinib), mTOR (rapamycin), and VEGF (bevacizumab). This article provides an update of the current multimodality treatment of cranial base chordomas, with an emphasis on how current understanding of molecular pathogenesis provides a framework for the development of novel targeted approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.